Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110
Benzinga Newsdesk 2 months ago
NewsUpgradesAnalyst RatingsPrice Target
Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $83 to $110.
Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $83 to $110.